Inflammatory bowel diseases (IBD), which include Crohn’s disease and ulcerative colitis, are chronic, lifelong conditions that affect millions of people worldwide.

These diseases cause debilitating symptoms such as abdominal pain, diarrhea, weight loss, fatigue, and rectal bleeding.

While there have been significant advancements in treatment over the years, many individuals with Crohn’s and ulcerative colitis experience what’s known as “refractory” disease, meaning their condition doesn’t adequately respond to standard therapies.

In this article, we’ll explore why clinical trials are essential for advancing care, especially for those living with refractory Crohn’s disease and ulcerative colitis.

Understanding Refractory IBD

Refractory Crohn’s disease and ulcerative colitis refer to cases where patients do not achieve significant relief from symptoms despite treatment with conventional medications such as corticosteroids, immunomodulators, or biologic agents.

For some individuals, even the most advanced therapies may not lead to remission or a substantial reduction in inflammation.

These patients face ongoing disease activity that impacts their quality of life and may lead to complications, including hospitalizations, surgeries, and even an increased risk of colorectal cancer.

In addition to disease resistance, some patients experience adverse reactions to standard treatments, further limiting their options.

This creates an urgent need for new and innovative therapies, which is where clinical trials play a critical role.

The Role of Clinical Trials in Advancing Treatment

Clinical trials are research studies designed to evaluate new treatments, therapies, or interventions in humans. These trials are conducted in carefully controlled settings to determine the safety, efficacy, and optimal use of a new therapy.

Each clinical trial typically goes through multiple phases before a treatment can be approved for widespread use:

1. Phase I Trials: These initial trials involve a small group of participants and focus on assessing the safety of the new treatment, determining dosage levels, and identifying potential side effects.

2. Phase II Trials: Once the safety profile is established, Phase II trials involve a larger group of participants to assess the treatment’s efficacy and further evaluate safety.

3. Phase III Trials: In this phase, the new treatment is compared to the current standard treatment to determine whether it offers significant benefits. These trials involve a larger population and collect more comprehensive data on the treatment’s effectiveness and safety.

4. Phase IV Trials: After a treatment is approved by regulatory agencies (like the FDA), Phase IV trials continue to monitor its long-term effects, side effects, and overall efficacy in a broader population.

Each of these phases is critical for ensuring that new treatments are both effective and safe for use in the general population.

For refractory Crohn’s and ulcerative colitis patients, clinical trials offer access to treatments that may provide relief when existing therapies have failed.

Why Clinical Trials Matter for Refractory Crohn’s and Ulcerative Colitis

1. Access to Innovative Therapies

One of the primary reasons why clinical trials matter for refractory IBD is that they provide patients with early access to cutting-edge therapies that are not yet available to the public.

For patients who have exhausted conventional treatment options, this access can be life changing.

Whether it’s a new biologic, small molecule drug, or an advanced combination therapy, clinical trials offer hope where standard care has fallen short.

Recent innovations include therapies targeting different immune pathways that play a role in inflammation, such as interleukin inhibitors, Janus kinase (JAK) inhibitors, and other biologics that inhibit specific molecules associated with the inflammatory process in the gut.

These therapies have shown promise in early clinical trials, providing remission or significant improvement for patients who had no other treatment options.

2. Personalized Medicine and Targeted Therapies

Clinical trials are also contributing to the development of personalized medicine for Crohn’s disease and ulcerative colitis.

By studying the genetic, microbial, and immune profiles of individual patients, researchers can identify which treatments are most likely to work for specific subtypes of the disease.

For example, certain biologics are more effective in patients with specific inflammatory markers.

By participating in clinical trials, patients with refractory IBD can benefit from treatments tailored to their unique disease characteristics, improving their chances of remission.

3. Contributing to Medical Knowledge

Every clinical trial is a crucial piece of the larger puzzle in understanding Crohn’s disease and ulcerative colitis. Even when a treatment doesn’t produce the desired outcome for an individual, the data collected during the trial contributes to the overall understanding of IBD.

This data helps researchers refine treatments, identify which patients are most likely to benefit, and develop new therapeutic approaches.

For refractory patients, participation in clinical trials allows them to contribute to the greater good of advancing IBD research. By volunteering for studies, patients are directly helping to improve future treatment options for themselves and others.

4. Monitoring and Care from Specialists

Patients who participate in clinical trials often receive more intensive monitoring and care from specialists than they might in standard clinical settings.

Regular check-ups, lab tests, imaging studies, and consultations with leading IBD experts are part of the trial process.

This enhanced care can lead to better disease management, early identification of complications, and improvements in overall health.

Additionally, clinical trial participants are typically treated with the highest standards of care, ensuring their safety is prioritized throughout the study.

5. Exploring New Treatment Combinations

Many clinical trials explore combinations of existing treatments to see if they can work together more effectively than when used alone.

For example, combining different biologics or using biologics alongside small molecule drugs may provide more comprehensive disease control.

These combination therapies are particularly important for refractory patients who may need a more aggressive treatment approach to control their symptoms.

6. Potential Cost Savings

Participating in a clinical trial can also reduce the financial burden on patients with refractory Crohn’s disease and ulcerative colitis.

In many cases, the costs associated with trial-related medications, tests, and healthcare visits are covered by the study sponsor.

For patients struggling with the costs of ongoing IBD treatment, this financial relief can be significant.

Addressing Concerns About Clinical Trials

While clinical trials offer many potential benefits, some patients may be hesitant to participate due to concerns about safety, side effects, or uncertainty about receiving a placebo.

1. Safety Protocols

Clinical trials are conducted with rigorous safety protocols in place. Before a trial begins, it must be reviewed and approved by an Institutional Review Board (IRB), which ensures that the study meets ethical and safety standards, as well as an independent Ethics committee. Participants are closely monitored throughout the trial, and any adverse effects are reported and addressed immediately.

2. Informed Consent

All participants in clinical trials must provide informed consent before enrolling. This process involves a thorough explanation of the trial’s purpose, procedures, potential risks, and benefits. Patients are encouraged to ask questions and fully understand the trial before deciding to participate.

3. Placebo Concerns

While some clinical trials involve placebos, others use active treatments in all groups. For patients who are concerned about receiving a placebo, it’s essential to discuss the study design with their healthcare provider to understand the likelihood and implications of receiving a placebo.

How to Get Involved in Clinical Trials

If you or someone you know is living with refractory Crohn’s disease or ulcerative colitis, exploring clinical trial options can be a valuable step. To find a suitable trial:

1. Consult Your Gastroenterologist: Start by discussing your interest in clinical trials with your healthcare provider. They can help you identify trials that align with your condition and treatment history.

2. Use Online Resources: Websites like ClinicalTrials.gov, the Crohn’s & Colitis Foundation, and local clinical research organizations often list available trials.

3. Talk to a Clinical Research Company: Companies specializing in clinical research, particularly those focusing on IBD, can guide you through the process and help match you with appropriate trials.

Conclusion

For patients with refractory Crohn’s disease and ulcerative colitis, clinical trials represent an essential avenue for accessing innovative treatments and contributing to the advancement of IBD care.

While participation in clinical trials involves careful consideration, the potential benefits—early access to new therapies, personalized treatment options, and close monitoring—make them an invaluable option for patients facing limited treatment success.

Through clinical trials, we can continue to make strides toward improving the lives of those living with these challenging chronic diseases.

Contact Dr. Gosia George

Dr Gosia George and Dr Eduan  Deetlefs are clinical investigators at Spoke Research Inc and became involved in Clinical Research in 2017, and now runs the Inflammatory Bowel Disease trials.

If you’d like to take part in a clinical trial, join us here:

Apply for Crohn’s Disease Trial

Apply for Ulcerative Colitis Trial

We are here to provide you with expert medical advice in the field of clinical research with years of experience.

Contact us to find out more on clinical trials and treatment.